Opyl secures AU$700,000 to boost TrialKey Platform

Opyl (ASX: OPL) has secured AU$ 700,000 through short-term loan agreements with Antanas "Tony" Guoga, Peak Asset Management, Rip Opportunities Pty Ltd, and Irwin Biotech Nominees Pty Ltd.

The funding will enhance the TrialKey platform, targeted marketing efforts, and general working capital. This financial boost is pivotal for advancing Opyl's growth strategy, particularly in driving marketing initiatives that support a robust sales pipeline. Furthermore, the investment will facilitate ongoing optimisation of the TrialKey platform. It will incorporate essential features based on client feedback and align with the company's product development roadmap, strengthening its position in the clinical trial industry.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com